An overview of genetic polymorphisms and pancreatic cancer risk in molecular epidemiologic studies

Journal of Epidemiology

Volumn 21, Issue 1, 2011, Pages 2-12

  Lin, Yingsong ^a   Yagyu, Kiyoko ^a   Egawa, Naoto ^b   Ueno, Makoto ^c   Mori, Mitsuru ^d   Nakao, Haruhisa ^a   Ishii, Hiroshi ^e   Nakamura, Kozue ^f   Wakai, Kenji ^g   Hosono, Satoyo ^h   Tamakoshi, Akiko ^a   Kikuchi, Shogo ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

^d SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e CANCER INSTITUTE HOSPITAL   (Japan)

^f GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Gene environment interaction; Genetic polymorphisms; Molecular epidemiology; Pancreatic cancer

Indexed keywords

GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; PANCREAS TUMOR; REVIEW; RISK FACTOR;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; PANCREATIC NEOPLASMS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 78651499950     PISSN: 09175040     EISSN: 13499092     Source Type: Journal    
DOI: 10.2188/jea.JE20100090     Document Type: Review

References (86)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Foundation for Promotion of Cancer Research. Cancer Statistics in Japan-2008.
3. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, et al. Pancreatic cancer registry in Japan: 20 years of experience. Pancreas. 2004;28:219-30.
4. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897-909.
5. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg. 2008;393:535-45.
6. Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92:2076-83.
7. Michaud DS. Epidemiology of pancreatic cancer. Minerva Chir. 2004;59:99-111.
8. Duell EJ, Holly EA, Bracci PM, Liu M, Wiencke JK, Kelsey KT. A population-based case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk. J Natl Cancer Inst. 2002;94:297-306.
9. Li D, Ahmed M, Li Y, Jiao L, Chou TH, Wolff RA, et al. 5,10-Methylenetetrahydrofolate reductase polymorphisms and the risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1470-6.
10. McWilliams RR, Bamlet WR, Cunningham JM, Goode EL, de Andrade M, Boardman LA, et al. Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk. Cancer Res. 2008;68:4928-35.
11. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009;41:986-90.
12. Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1, 5p15.33. Nat Genet. 2010;42:224-8.
13. Schenk M, Schwartz AG, O'Neal E, Kinnard M, Greenson JK, Fryzek JP, et al. Familial risk of pancreatic cancer. J Natl Cancer Inst. 2001;93:640-4.
14. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20:1218-49.
15. Hecht SS. Tobacco carcinngens, their biomarkers and tobaccorelated cancer. Nat Rev Cancer. 2003;3:733-44.
16. Thompson PA, Seyedi F, Lang NP, MacLeod SL, Wogan GN, Anderson KE, et al. Comparison of DNA adduct levels associated with exogenous and endogenous exposures in human pancreas in relation to metabolic genotype. Mutat Res. 1999;424:263-74.
17. Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signaling pathways and environmental carcinogenesis. Nat Rev Cancer. 2006;6:947-60.
18. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1997;6:733-43.
19. Geisler SA, Olshan AF. GSTM1, GSTT1, and the risk of squamous cell carcinoma Lin 30 of the head and neck: a mini-HuGE review. Am J Epidemiol. 2001;154:95-105.
20. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 2000;9:29-42.
21. Li D, Jiao L, Li Y, Doll MA, Hein DW, Bondy ML, et al. Polymorphisms of cytochome P4501A2 and N-acetyltransferase genes, smoking and risk of pancreatic cancer. Carcinogenesis. 2006;27:103-11.
22. Jiao L, Doll MA, Hein DW, Bondy ML, Hassan MM, Hixson JE, et al. Haplotype of N-Acetyltransferase 1 and 2 and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:2379-86.
23. Jiao L, Bondy ML, Hassan MM, Chang DZ, Abbruzzese JL, Evans DB, et al. Glutathione S-transferase gene polymorphisms and risk and survival of pancreatic cancer. Cancer. 2007;109:840-8.
24. Suzuki H, Morris JS, Li Y, Doll MA, Hein DW, Liu J, et al. Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphism with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. Carcinogenesis. 2008;29:1184-91.
25. Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K. Genetic polymorphisms of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev. 2000;9:3-28.
26. Liu G, Ghadirian P, Vesprini D, Hamel N, Paradis AJ, Lal G, et al. Polymorphisms in GSTM1, GSTT1, and CYP1A1 and risk of pancreatic adenocarcinoma. Br J Cancer. 2000;82:1646-9.
27. Lee HC, Yoon YB, Kim CY. Association between genetic polymorphisms of the cytochromes P-450 (1A1, 2D6, and 2E1) and the susceptibility to pancreatic cancer. Korean J Intern Med. 1997;12:128-36.
28. David SS, O'Shea VL, Kundu S. Base-excision repair of oxidative DNA damage. Nature. 2007;447:941-50.
29. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol. 2004;44:239-67.
30. Hung RJ, Hall J, Brennan P, Boffetta P. Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol. 2005;162:925-42.
31. Duell EJ, Holly EA, Bracci PM, Wiencke JK, Kelsey KT. A population-based study of Arg399Gln polymorphism in X-Ray Repair Cross-Complementing Group1 (XRCC1) and risk of pancreatic adenocarcinoma. Cancer Res. 2002;62:4630-6.
32. Li D, Li Y, Jiao L, Chang DZ, Beinart G, Wolff RA, et al. Effects of base excision repair gene polymorphisms on pancreatic cancer survival. Int J Cancer. 2007;120:1748-54.
33. Jiao L, Hassan MM, Bondy ML, Wolff RA, Evans DB, Abbruzzese JL, et al. XRCC2 and XRCC3 gene polymorphisms and risk of pancreatic cancer. Am J Gastroenterol. 2008;103:360-7.
34. Li D, Frazier M, Evans DB, Hess KR, Crane CH, Jiao L, et al. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol. 2006;24:1720-8.
35. Jiao L, Hassan MM, Bondy ML, Abbruzzese JL, Evans DB, Li D. The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk. Cancer Lett. 2007;245:61-8.
36. Kim YI. Folate and carcinogenesis: evidence, mechanisms, and implications. J Nutr Biochem. 1999;10:66-88.
37. Larsson SC, Håkansson N, Giovannucci E, Wolk A. Folate intake and pancreatic cancer incidence: a prospective study of Swedish women and men. J Natl Cancer Inst. 2006;98:407-13.
38. Larsson SC, Giovannucci E, Wolk A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology. 2006;131:1271-83.
39. Lucock M, Yates Z. Folic acid-vitamin and panacea or genetic time bomb? Nat Rev Genet. 2005;6:235-40.
40. Wang L, Miao X, Tan W, Lu X, Zhao P, Zhao X, et al. Genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase and risk of pancreatic cancer. Clin Gastroenterol Hepatol. 2005;3:743-51.
41. Matsubayashi H, Skinner HG, Iacobuzio-Donahue C, Abe T, Sato N, Riall TS, et al. Pancreaticobiliary cancer with deficient methylenetetrahydrofolate reductase genotypes. Clin Gastroenterol Hepatol. 2005;3:752-60.
42. Suzuki T, Matsuo K, Sawaki A, Mizuno N, Hiraki A, Kawase T, et al. Alcohol drinking and one-carbon metabolism-related gene polymporphisms on pancreatic cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17:2742-7.
43. Ohnami S, Sato Y, Yoshimura K, Ohnami S, Sakamoto H, Aoki K, et al. His595Tyr polymorphisms in the methionine synthase reductase (MTRR) gene is associated with pancreatic cancer risk. Gastroenterology. 2008;135:477-88.
44. Silverman DT, Brown LM, Hoover RN, Schiffman M, Lillemoe KD, Schoenberg JB, et al. Alcohol and pancreatic cancer in black and whites in the United States. Cancer Res. 1995;55:4899-905.
45. Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer. 2007;7:599-612.
46. Kanda J, Matsuo K, Suzuki T, Kawase T, Hiraki A, Watanabe M, et al. Impact of alcohol consumption with polymorphisms in alcohol-metabolizing enzymes on pancreatic cancer risk in Japanese. Cancer Sci. 2008;100:296-302.
47. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-81.
48. Raimondi S, Johansson H, Maisonneuve P, Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009;30:1170-80.
49. Campbell FC, Xu H, El-Tanani M, Crowe P, Bingham V. The Yin and Yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control. Biochem Pharmacol. 2010;79:1-9.
50. Stolzenberg-Solomon RZ. Vitamin D and pancreatic cancer. Ann Epidemiol. 2009;19:89-95.
51. Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer prevention: globe perspective. Ann Epidemiol. 2009;19:468-83.
52. Filipski E, King VM, Li X, Granda TG, Mormont MC, Liu X, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst. 2002;94:690-7.
53. Davis S, Mirick DK. Circadian disruption, shift work and risk of cancer: a summary of the evidence and studies in Seattle. Cancer Causes Control. 2006;17:539-45.
54. IARC. IARC monographs on the evaluation of carcinogenic risks to humans; volume 98, Shift work, painting and firefighting. Lyon: International Agency for Research on Cancer.
55. Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336:186-95.
56. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proença C, Sparsø T, Holmkvist J, Marchand M, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009;41:89-94.
57. Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spégel P, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 2009;41:82-8.
58. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2009;41:77-81.
59. Mühlbauer E, Peschke E. Evidence for the expression of both the MT-1 and in addition, the MT-2-melatonin receptor, in the rat pancreas, islet and beta-cell. J Pineal Res. 2007;42:105-6.
60. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. 2003;3:350-61.
61. Zhu Y, Stevens RG, Hoffman AE, Fitzgerald LM, Kwon EM, Ostrander EA, et al. Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res. 2009;69:9315-22.
62. McCarty MF. Insulin secretion as a determinant of pancreatic cancer risk. Med Hypotheses. 2001;57:146-50.
63. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799-806.
64. Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 1995;55:2007-11.
65. Lin Y, Tamakoshi A, Kikuchi S, Yagyu K, Obata Y, Ishibashi T, et al. Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death. Int J Cancer. 2004;110:584-8.
66. Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, et al. Circulating insulin-like growth factors axis and the risk of pancreatic cancer in four prospective studies. Br J Cancer. 2007;97:98-104.
67. Suzuki H, Li Y, Dong X, Hassan MM, Abbruzzese JL, Li D. Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:3467-73.
68. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor ( in human disease. N Engl J Med. 2000;342:1350-8.
69. Massagué J. TGFβ in cancer. Cell. 2008;134:215-30.
70. Truty MJ, Urrutia R. Basics of TGF-β and pancreatic cancer. Pancreatology. 2007;7:423-35.
71. Tascilar M, Skinner HG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ, et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2001;7:4115-21.
72. Kaklamani VG, Hou N, Bian Y, Reich J, Offit K, Michel LS, et al. TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol. 2003;21:3236-43.
73. Williams CS, Mann M, DuBois RN. The role of cyclooxygenase in inflammation, cancer, and development. Oncogene. 1999;18:7908-16.
74. Juuti A, Louhimo J, Nordling S, Ristimäki A, Haglund C. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol. 2006;59:382-6.
75. Zhao D, Xu D, Zhang X, Wang L, Tan W, Guo Y, et al. Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin. Gastroenterology. 2009;136:1659-68.
76. Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15:726-31.
77. Risch HA. Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. J Natl Cancer Inst. 2003;95:948-60.
78. Hardy J, Singleton A. Genome-wide association studies in human disease. N Engl J Med. 2009;360:1759-68.
79. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analysis. Science. 2008;321:1801-6.
80. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 2005;39:359-407.
81. Navaglia F, Basso D, Fogar P, Sperti C, Greco E, Zambon CF, et al. Mitochondrial DNA D-loop in pancreatic cancer: somatic mutations are epiphenomena while the germline 16519 T variant worsens metabolism and outcome. Am J Clin Pathol. 2006;126:593-601.
82. Halfdanarson TR, Wang L, Bamlet WR, de Andrade M, McWilliams RR, Cunningham JM, et al. Mitochondrial genetic polymorphisms do not predict survival in patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:2512-3.
83. Wang L, Bamlet WR, de Andrade M, Boardman LA, Cunningham JM, Thibodeau SN, et al. Mitochondrial genetic polymorphisms and pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:1455-9.
84. Wain LV, Armour JA, Tobin MD. Genomic copy number variation, human health, and disease. Lancet. 2009;374:340-50.
85. Krechler T, Jachymova M, Pavlikova M, Vecka M, Zeman M, Krska Z, et al. Polymorphism -23HPhI in the promoter of insulin gene and pancreatic cancer: a pilot study. Neoplasma. 2009;56:26-32.
86. Lucito R, Suresh S, Walter K, Pandey A, Lakshmi B, Krasnitz A, et al. Copy-number variants in patients with a strong family history of pancreatic cancer. Cancer Biol Ther. 2007;10:1592-9.